 |
|
|
| |
IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE 3 REALIZE STUDY
|
| |
| |
Reported by Jules Levin
Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Graham R Foster1, Stuart Roberts2, Stanislas Pol3, Pietro Andreone4, Eric J Lawitz5, Zobair Younossi6, Isabelle Lonjon-Domanec7, Rolf van Heeswijk8, Gaston Picchio9, Stefan Zeuzem10
1Queen Mary University of London, Institute of Cell and Molecular Science, London, United Kingdom; 2Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 3Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France; 4Universita di Bologna, Bologna, Italy; 5Alamo Medical Research, San Antonio, TX, USA; 6Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 7Janssen Pharmaceuticals, Paris, France; 8Janssen Infectious Diseases BVBA, Beerse, Belgium; 9Janssen Research & Development, Titusville, NJ, USA; 10Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
from Jules: so why are outcomes different here than in CUPIC? Well to begin with perhaps the patients in CUPIC had much more advanced liver disease., in CUPIC it was reported that 19-28% had esophageal varisces, I don't think although I'm not sure that these types of patients would have qualified for REALIZE Study. The overall rates of anemia in this analysis are similar to those previously reported overall anemia outcomes in ADVANCE & REALIZE.
|
| |
|
|
|
|
|
